Pharma has a speed problemand its not just about clinical timelines.
In the race to launch, the winners arent always the companies with the most compelling science. Theyre the ones that treat intellectual property like a commercial asset with a clock a…
Dont Get Blind-Sided: The Critical Drug Patent Mistakes to Avoid in MA Due Diligence
In Massachusetts, due diligence cant be a checkbox exerciseespecially when the asset youre evaluating is a drug product with a patent landscape thats anything but stat…
Don’t Get Blind-Sided: The Critical Drug Patent Mistakes to Avoid in M&A Due Diligence Read Post »
Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…
Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…
The 20-Year Myth Is Costing PharmaHeres What Actually Determines Drug Exclusivity
If youve ever heard that a drugs market exclusivity is simply 20 years, youve heard a comforting simplificationone that can lead to expensive misreads of timing, strategy…
Beyond 20 Years: What Actually Determines a Drug’s Market Exclusivity Read Post »
Pharma mega-deals dont happen because of synergy slides. They happen because of exclusivity.
Behind every headline acquisitionevery blockbuster asset changing hands for billionstheres a quiet, technical question that determines whether a buyer is buyin…
The Four Exclusivities Behind Every Pharma Mega-Deal Read Post »
The Patent Cliff Isnt a MomentIts a Timeline. Heres How to Forecast Drug Price Erosion Before It Hits.
If youve worked in pharma finance, strategy, or market access, you already know the headline: patents expire, exclusivity ends, generics and biosimil…
Patent Cliff Forecasting: How to Predict Drug Price Erosion Before It Happens Read Post »
Post-approval is where many drug strategies quietly fail.
The science may be done. The trial results may be in. But the real riskregulatory and IPoften accelerates after approval, not before. If youre a pharma leader, counsel, or BD executive, the ques…
Post-approval is where the real IP game starts.
Most teams obsess over getting to approval—then quietly assume the hard part is over. It isn’t. In the months and years after launch, your product becomes a target: for generic challengers, for “evergre…
Pharma companies dont lose exclusivity because they missed a deadline. They lose it because they misread the battlefield.
In patent strategy, the real risk isnt just litigationits litigation plus the erosion of market position that comes when challenge…
Pharma Patent Strategy: How to Defend Exclusivity Without Getting Sued Read Post »
Get new actionable insights and updates from BiotechBlog
